p53 Gene Status and Response to Topotecan-Containing Chemotherapy in Advanced Ovarian Carcinoma

Publisher： Karger

E-ISSN： 1423-0232|69|2|154-158

ISSN： 0030-2414

Source： Oncology, Vol.69, Iss.2, 2005-09, pp. : 154-158

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

p53 Gene Mutation, Microsatellite Instability and Adjuvant Chemotherapy: Impact on Survival of 388 Patients with Dukes’ C Colon Carcinoma

By  

Oncology, Vol. 58, Iss. 1, 2000-01 ,pp. : 52-59

Karger

Access to resources Recommend Favorite

Alteration of a p53 Gene Status Affects Outcome of Patients with Recurrent Ovarian Cancer

By  

Oncology, Vol. 58, Iss. 3, 2000-04 ,pp. : 237-241

Karger

Access to resources Recommend Favorite

Prognostic Value of Multidrug Resistance 1, Glutathione-S-Transferase-π and p53 in Advanced Nasopharyngeal Carcinoma Treated with Systemic Chemotherapy

By  

Oncology, Vol. 62, Iss. 4, 2002-07 ,pp. : 305-312

Karger

Access to resources Recommend Favorite

Improved Overall Survival with 12 Cycles of Single-Agent Paclitaxel Maintenance Therapy following a Complete Response to Induction Chemotherapy in Advanced Ovarian Carcinoma

By  

Oncology, Vol. 78, Iss. 5-6, 2010-08 ,pp. : 389-393

Karger

Access to resources Recommend Favorite

Importance of Topotecan in the Therapy of Ovarian Carcinoma, Today and Tomorrow

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1999-01 ,pp. : 6-9

Karger

Access to resources Recommend Favorite